Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triptorelin + progesterone
- Development stage
- Phase 4
- Lead developer
- Assiut University
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Vaginal
01
Overview
This combination therapy consists of the gonadotropin-releasing hormone (GnRH) agonist triptorelin and the steroid hormone progesterone, utilized as luteal phase support (LPS) in assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Triptorelin acts as an agonist at the GnRH receptor in the pituitary gland, inducing a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that stimulates the corpora lutea to enhance endogenous steroid synthesis. Progesterone provides direct exogenous hormonal support to the endometrium, facilitating embryo implantation and maintaining early pregnancy. This specific investigational protocol typically involves a single mid-luteal dose of triptorelin (0.1 mg) administered subcutaneously on day 6 after oocyte pickup, in addition to standard transvaginal progesterone supplementation.
- Other names
- gonadotropins releasing hormone agonist + progesteroneGnRHa + progesteronetriptorelin and progesterone
02
Targets
AR (Adrenergic receptors)GR (Glucocorticoid receptor)GnRHR (Gonadotropin-releasing hormone receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on triptorelin + progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triptorelin + progesterone.